Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors. Context is building an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 bispecific antibody, CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific antibody. Context is headquartered in Philadelphia. For more information, visit www.contexttherapeutics.com.
Company Details
- Employees
- 23
- Founded
- -
- Address
- 2001 Market Street, Philadelphia,pennsylvania 19103,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- contexttherapeutics.com
- Keywords
- Oncology and Bispecific Antibody.
- HQ
- Philadelphia, Pennsylvania
Context Therapeutics Questions
Context Therapeutics's website is contexttherapeutics.com
Context Therapeutics's LinkedIn profile is https://www.linkedin.com/company/context-therapeutics
Context Therapeutics has
23 employees.
View email and phone details for 23
employees at Context Therapeutics.
Context Therapeutics's industry is
Biotechnology Research
Context Therapeutics's top competitors are
Excision Biotherapeutics,
Verismo Therapeutics,
Century Therapeutics, Inc,
Bioatla, Inc.,
Interius Biotherapeutics,
Harmony Biosciences,
Carisma Therapeutics,
Cabaletta Bio,
Adaptimmune,
Delphia Therapeutics.
Context Therapeutics's categories are Biotechnology Research
Context Therapeutics's founding year is 2015
